CoChat

Inflammation Induces TDP-43 Mislocalization and Aggregation

Open access

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Abstract

TAR DNA-binding protein 43 (TDP-43) is a major component in aggregates of ubiquitinated proteins in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). Here we report that lipopolysaccharide (LPS)-induced inflammation can promote TDP-43 mislocalization and aggregation. In culture, microglia and astrocytes exhibited TDP-43 mislocalization after exposure to LPS. Likewise, treatment of the motoneuron-like NSC-34 cells with TNF-alpha (TNF-α) increased the cytoplasmic levels of TDP-43. In addition, the chronic intraperitoneal injection of LPS at a dose of 1mg/kg in TDP-43(A315T) transgenic mice exacerbated the pathological TDP-43 accumulation in the cytoplasm of spinal motor neurons and it enhanced the levels of TDP-43 aggregation. These results suggest that inflammation may contribute to development or exacerbation of TDP-43 proteinopathies in neurodegenerative disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0140248

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 No change in mRNA expression for TDP-43 species due to LPS treatment. (A) Representative images of primary astrocytes and microglia cultures double stained for Iba 1(in red, marker of microglia) and GFAP (in green, marker of astrocytes). Nuclei of all cells were stained with DAPI (in blue). Using this double immunostaining we confirmed that we achieved a good separation of astrocytes from microglia, and resulting cultures were ~ 90% pure in one of the cell types. (B) Total RNA was extracted from LPS-treated (1ug/ml LPS for 1 day) and untreated cultures of astrocytes and microglia. Samples of total RNA were then subjected to real-time quantitative RT-PCR for human TDP-43 (hTDP-43, transgene) and mouse TDP-43 (mTDP-43, endogenous gene). Number of copies of hTDP-43 and mTDP-43 were normalized with the house-keeping gene Atp5 mRNA, in order to take in account variations in samples size. Levels of RNA in the LPS-treated sample were divided by the levels of mRNA in the respective untreated control, in order to get the fold changes in the expression with the LPS-treatment. Fold change equal to 1 indicate no effect of LPS in the expression of the gene, which was seen in most of the cultures analyzed for both mouse and human TDP-43.
Fig 1 No change in mRNA expression for TDP-43 species due to LPS treatment. (A) Representative images of primary astrocytes and microglia cultures double stained for Iba 1(in red, marker of microglia) and GFAP (in green, marker of astrocytes). Nuclei of all cells were stained with DAPI (in blue). Using this double immunostaining we confirmed that we achieved a good separation of astrocytes from microglia, and resulting cultures were ~ 90% pure in one of the cell types. (B) Total RNA was extracted from LPS-treated (1ug/ml LPS for 1 day) and untreated cultures of astrocytes and microglia. Samples of total RNA were then subjected to real-time quantitative RT-PCR for human TDP-43 (hTDP-43, transgene) and mouse TDP-43 (mTDP-43, endogenous gene). Number of copies of hTDP-43 and mTDP-43 were normalized with the house-keeping gene Atp5 mRNA, in order to take in account variations in samples size. Levels of RNA in the LPS-treated sample were divided by the levels of mRNA in the respective untreated control, in order to get the fold changes in the expression with the LPS-treatment. Fold change equal to 1 indicate no effect of LPS in the expression of the gene, which was seen in most of the cultures analyzed for both mouse and human TDP-43.CC BY · PubMed Central
Fig 2 Higher levels of TDP-43 protein in LPS-activated astrocytes and microglia. Cultured astrocytes and microglia from transgenic (hTDP-43A315T) and non-transgenic litters were treated for 1 day with LPS at 1 μg/ml or 0.1 μg/ml. Total protein was extracted from LPS -treated and untreated cultures and analysed by immunoblotting. TDP-43 was detected using the polyclonal antibody (Proteintech # 10782-AP) which reacts with both human (transgenic) and mouse (endogenous) proteins. TDP-43 bands were normalized against actin to take into account the difference in protein loading. The exposure times are actually different between transgenic and non-transgenic blots. Due to higher quantities of TDP-43 (human plus mouse) in the transgenic cell cultures the exposure time was only 30 seconds whereas for the non-transgenic cultures it was 4 minutes. Fold change is the ratio of band intensity in LPS-treated cultures over the band intensity in the respective untreated control. (A) Representative western blot of TDP-43 from LPS treated or untreated astrocyte culture. (B) Quantitative analysis of western blot showed that levels of total TDP-43 was higher in LPS treated transgenic astrocyte culture than non-transgenic culture. (C) Representative western blot of TDP-43 from LPS treated or untreated microglia culture. (D) Quantitative analysis of western blot showed that levels of total TDP-43 were also higher in LPS-treated microglia from transgenic TDP-43A315T mice than from C57BL6 mice.
Fig 2 Higher levels of TDP-43 protein in LPS-activated astrocytes and microglia. Cultured astrocytes and microglia from transgenic (hTDP-43A315T) and non-transgenic litters were treated for 1 day with LPS at 1 μg/ml or 0.1 μg/ml. Total protein was extracted from LPS -treated and untreated cultures and analysed by immunoblotting. TDP-43 was detected using the polyclonal antibody (Proteintech # 10782-AP) which reacts with both human (transgenic) and mouse (endogenous) proteins. TDP-43 bands were normalized against actin to take into account the difference in protein loading. The exposure times are actually different between transgenic and non-transgenic blots. Due to higher quantities of TDP-43 (human plus mouse) in the transgenic cell cultures the exposure time was only 30 seconds whereas for the non-transgenic cultures it was 4 minutes. Fold change is the ratio of band intensity in LPS-treated cultures over the band intensity in the respective untreated control. (A) Representative western blot of TDP-43 from LPS treated or untreated astrocyte culture. (B) Quantitative analysis of western blot showed that levels of total TDP-43 was higher in LPS treated transgenic astrocyte culture than non-transgenic culture. (C) Representative western blot of TDP-43 from LPS treated or untreated microglia culture. (D) Quantitative analysis of western blot showed that levels of total TDP-43 were also higher in LPS-treated microglia from transgenic TDP-43A315T mice than from C57BL6 mice.CC BY · PubMed Central
Fig 3 Cytoplasmic increase of TDP-43 in LPS-activated astrocytes. Representative images of astrocytes from hTDP-43A315T transgenic and non-transgenic littermates, treated or not treated with LPS (1 μg/ml) for one day. Astrocytes are double stained for TDP-43 (red) and GFAP (green) while nuclei are stained with DAPI (blue). Immunofluorescence for TDP-43 increased in the cytoplasm of LPS-treated astrocytes in both non transgenic (2nd panel) and transgenic culture (4th panel) as compared to the untreated control (1st and 3rd panel). However, the overall cytoplasmic increase of TDP-43 was more pronounced in LPS-treated astrocytes from hTDP-43A315T transgenic mice than in LPS-treated astrocytes from C57Bl6 mice. Arrows point on cells presenting a decrease in nuclear TDP-43. Scale bar 100μm.
Fig 3 Cytoplasmic increase of TDP-43 in LPS-activated astrocytes. Representative images of astrocytes from hTDP-43A315T transgenic and non-transgenic littermates, treated or not treated with LPS (1 μg/ml) for one day. Astrocytes are double stained for TDP-43 (red) and GFAP (green) while nuclei are stained with DAPI (blue). Immunofluorescence for TDP-43 increased in the cytoplasm of LPS-treated astrocytes in both non transgenic (2nd panel) and transgenic culture (4th panel) as compared to the untreated control (1st and 3rd panel). However, the overall cytoplasmic increase of TDP-43 was more pronounced in LPS-treated astrocytes from hTDP-43A315T transgenic mice than in LPS-treated astrocytes from C57Bl6 mice. Arrows point on cells presenting a decrease in nuclear TDP-43. Scale bar 100μm.CC BY · PubMed Central
Fig 4 Cytoplasmic aggregates of TDP-43 in LPS-activated microglia. Representative images of microglia from hTDP-43A315T transgenic and control littermates, treated or not treated with LPS (1μg/ml) for one day. Microglial cultures were double stained for polyclonal TDP-43 (red) and CD11b (green) whereas the nuclei were stained with DAPI (blue). No cytoplasmic aggregates of TDP-43 were found in untreated microglia from control C57Bl6 mice (1st panel) or from hTDP-43A315T transgenic mice (3rd panel). Treatment with LPS resulted in formation of small cytoplasmic TDP-43 aggregates in microglia from control C57Bl6 mice (2nd panel) and from hTDP-43A315T transgenic mice (4th panel). However, TDP-43 punctate aggregates were more abundant and of higher intense staining in LPS-treated microglia (4th panel) from hTDP-43A315T transgenic when compared to microglia from C57Bl6 mice (2nd panel). Arrowheads point to cells with cytoplasmic aggregates of TDP-43.
Fig 4 Cytoplasmic aggregates of TDP-43 in LPS-activated microglia. Representative images of microglia from hTDP-43A315T transgenic and control littermates, treated or not treated with LPS (1μg/ml) for one day. Microglial cultures were double stained for polyclonal TDP-43 (red) and CD11b (green) whereas the nuclei were stained with DAPI (blue). No cytoplasmic aggregates of TDP-43 were found in untreated microglia from control C57Bl6 mice (1st panel) or from hTDP-43A315T transgenic mice (3rd panel). Treatment with LPS resulted in formation of small cytoplasmic TDP-43 aggregates in microglia from control C57Bl6 mice (2nd panel) and from hTDP-43A315T transgenic mice (4th panel). However, TDP-43 punctate aggregates were more abundant and of higher intense staining in LPS-treated microglia (4th panel) from hTDP-43A315T transgenic when compared to microglia from C57Bl6 mice (2nd panel). Arrowheads point to cells with cytoplasmic aggregates of TDP-43.CC BY · PubMed Central
Fig 5 Translocation of TDP-43 from the nucleus to the cytoplasm in astrocytes and microglia with LPS-treatment. (A) Nuclear and cytoplasmic protein fractions of astrocytes were analyzed by Western blot. The intensity of the 43kDa TDP-43 bands was divided by the intensity of the respective actin band to take in account the differences in the protein loading. Fold change is the ratio of the 43 kDa band intensity in the LPS-treated cultures over the band intensity in the respective untreated controls, after normalized by the intensity of the correspondent actin bands.
Fig 5 Translocation of TDP-43 from the nucleus to the cytoplasm in astrocytes and microglia with LPS-treatment. (A) Nuclear and cytoplasmic protein fractions of astrocytes were analyzed by Western blot. The intensity of the 43kDa TDP-43 bands was divided by the intensity of the respective actin band to take in account the differences in the protein loading. Fold change is the ratio of the 43 kDa band intensity in the LPS-treated cultures over the band intensity in the respective untreated controls, after normalized by the intensity of the correspondent actin bands.CC BY · PubMed Central
Fig 6 LPS treatment caused changes in nuclear and cytosolic TDP-43 immunostaining intensities in microglia cultures. The staining intensities were measured using the software Imaris on images taken with the confocal microscope Olympus IX81 and the software Olympus Fluoview ver 3.1a. More than 50 cells were analysed per cultures, 3 cultures of transgenic microglia and 3 cultures of non-transgenic microglia (N = 3). Fold changes were calculated by dividing the average intensities in the LPS-treated cultures over the average intensities in the untreated cultures. Graphic bars represent average and standard error of the mean values calculated with software GraphPad Prism 5.
Fig 6 LPS treatment caused changes in nuclear and cytosolic TDP-43 immunostaining intensities in microglia cultures. The staining intensities were measured using the software Imaris on images taken with the confocal microscope Olympus IX81 and the software Olympus Fluoview ver 3.1a. More than 50 cells were analysed per cultures, 3 cultures of transgenic microglia and 3 cultures of non-transgenic microglia (N = 3). Fold changes were calculated by dividing the average intensities in the LPS-treated cultures over the average intensities in the untreated cultures. Graphic bars represent average and standard error of the mean values calculated with software GraphPad Prism 5.CC BY · PubMed Central
Fig 7 TNF-α increases cytoplasmic localization of TDP-43 in NSC-34 cells. Non-transfected NSC-34 cells and hTDP-43WT-HA stably-transfected NSC-34 cells were treated with recombinant TNF-α at a concentration of 10 ng/mL for 6h. Non-TNF treated cells served as controls. Following treatment, the subcellular distribution of TDP-43 was determined by Western blot analysis. Immunoblotting with polyclonal TDP-43 antibody showed increased cytoplasmic TDP-43 in TNF-α-treated NSC-34 cells (left first panel) and hTDP-43WT-HA stably transfected cells (right first panel). Similarly, immunoblotting with monoclonal TDP-43 antibody (specific for human TDP-43) showed increased levels of cytoplasmic TDP-43 in TNF-α-treated hTDP-43WT-HA stably-transfected NSC-34 cells (2nd left panel). Immunoblots were reprobed with P84 antibody (nuclear marker) and GAPDH antibody (cytoplasmic marker).
Fig 7 TNF-α increases cytoplasmic localization of TDP-43 in NSC-34 cells. Non-transfected NSC-34 cells and hTDP-43WT-HA stably-transfected NSC-34 cells were treated with recombinant TNF-α at a concentration of 10 ng/mL for 6h. Non-TNF treated cells served as controls. Following treatment, the subcellular distribution of TDP-43 was determined by Western blot analysis. Immunoblotting with polyclonal TDP-43 antibody showed increased cytoplasmic TDP-43 in TNF-α-treated NSC-34 cells (left first panel) and hTDP-43WT-HA stably transfected cells (right first panel). Similarly, immunoblotting with monoclonal TDP-43 antibody (specific for human TDP-43) showed increased levels of cytoplasmic TDP-43 in TNF-α-treated hTDP-43WT-HA stably-transfected NSC-34 cells (2nd left panel). Immunoblots were reprobed with P84 antibody (nuclear marker) and GAPDH antibody (cytoplasmic marker).CC BY · PubMed Central
Fig 8 Chronic LPS treatment exacerbated cytoplasmic mislocalization and aggregation of TDP-43 in hTDP-43A315T transgenic mice. Non-transgenic and transgenic mice expressing hTDP-43A315T mutant at 6 months of age were i.p. injected with LPS (1mg/kg) or vehicle solution once per week up to 2 months. (A) Representative images of spinal cord sections of non-transgenic and hTDP-43A315T transgenic mice, vehicle and LPS treated were double stained with polyclonal TDP-43 (green) and Neu N (red). (B) Measurement of cytoplasmic to nuclear ratio of TDP-43 staining showed increased ratio in LPS treated transgenic as well as non-transgenic mice (N = 4 per group, 8 sections of spinal cord from 4 different animals for each group, *<0.05, **<0.001 by student’s t test.) (C) Chronic treatment of hTDP-43A315T transgenic mice with LPS enhanced levels of insoluble TDP-43 in spinal cord. Total protein was extracted from spinal cords of LPS or vehicle-treated mice and sub-fractionated into insoluble and soluble fractions. Sub-fractionated samples were then analyzed by Western blot using the polyclonal TDP-43 antibody. (D) The intensity of TDP-43 bands were divided by the intensity of the respective actin band to take in account the differences in the protein loading and then the fold change was calculated. The fold change is the ratio of the band intensity in the LPS-treated mice over the band intensity in the respective vehicle-treated controls. Fold changes are all higher than 1, indicating that LPS treatment led to increased levels of TDP-43 protein. Groups were compared using t-test. *p value = 0.03 by student’s t test (N = 4 per group, spinal cord from 4 different animals were used to extract protein for each group). Scale bar 50μm.
Fig 8 Chronic LPS treatment exacerbated cytoplasmic mislocalization and aggregation of TDP-43 in hTDP-43A315T transgenic mice. Non-transgenic and transgenic mice expressing hTDP-43A315T mutant at 6 months of age were i.p. injected with LPS (1mg/kg) or vehicle solution once per week up to 2 months. (A) Representative images of spinal cord sections of non-transgenic and hTDP-43A315T transgenic mice, vehicle and LPS treated were double stained with polyclonal TDP-43 (green) and Neu N (red). (B) Measurement of cytoplasmic to nuclear ratio of TDP-43 staining showed increased ratio in LPS treated transgenic as well as non-transgenic mice (N = 4 per group, 8 sections of spinal cord from 4 different animals for each group, *<0.05, **<0.001 by student’s t test.) (C) Chronic treatment of hTDP-43A315T transgenic mice with LPS enhanced levels of insoluble TDP-43 in spinal cord. Total protein was extracted from spinal cords of LPS or vehicle-treated mice and sub-fractionated into insoluble and soluble fractions. Sub-fractionated samples were then analyzed by Western blot using the polyclonal TDP-43 antibody. (D) The intensity of TDP-43 bands were divided by the intensity of the respective actin band to take in account the differences in the protein loading and then the fold change was calculated. The fold change is the ratio of the band intensity in the LPS-treated mice over the band intensity in the respective vehicle-treated controls. Fold changes are all higher than 1, indicating that LPS treatment led to increased levels of TDP-43 protein. Groups were compared using t-test. *p value = 0.03 by student’s t test (N = 4 per group, spinal cord from 4 different animals were used to extract protein for each group). Scale bar 50μm.CC BY · PubMed Central
Fig 9 Chronic LPS treatment enhanced nuclear exclusion of TDP-43 in spinal neurons of hTDP-43A315T transgenic mice. Transgenic mice expressing hTDP-43A315T mutant at 6 months of age were i.p. injected with LPS (1mg/kg) or vehicle solution once per week for a period of 2 months. (A) Spinal cord sections from LPS and vehicle-treated mice were immunostained with monoclonal antibody specific for human TDP-43. As revealed by immunostaining, more neuronal cells in LPS-treated spinal cord sections exhibited loss of nuclear TDP-43 staining (first and second panels) than vehicle (third and fourth panels). Insets in the first and second panels show magnified motor neurons of LPS-treated mice with nuclear loss of TDP-43. Arrow heads in first and second panels show neurons exhibiting nuclear loss of TDP-43 in LPS-treated hTDP-43A315T tg mice while arrows in third and fourth panel show neurons exhibiting nuclear loss of TDP-43 in vehicle-treated hTDP-43A315T tg mice. All representative sections are from different mice for each treatment group. DAPI was used to stain nuclei. Scale bar = 50μm. (B) Number of spinal neurons per section exhibiting nuclear loss of TDP-43 was higher in LPS-treated mice as compared to vehicle-treated mice (p = 0.043 by student’s t test, N = 4, 6 spinal cord sections from 4 different animals at 8 months were analyzed for each group).
Fig 9 Chronic LPS treatment enhanced nuclear exclusion of TDP-43 in spinal neurons of hTDP-43A315T transgenic mice. Transgenic mice expressing hTDP-43A315T mutant at 6 months of age were i.p. injected with LPS (1mg/kg) or vehicle solution once per week for a period of 2 months. (A) Spinal cord sections from LPS and vehicle-treated mice were immunostained with monoclonal antibody specific for human TDP-43. As revealed by immunostaining, more neuronal cells in LPS-treated spinal cord sections exhibited loss of nuclear TDP-43 staining (first and second panels) than vehicle (third and fourth panels). Insets in the first and second panels show magnified motor neurons of LPS-treated mice with nuclear loss of TDP-43. Arrow heads in first and second panels show neurons exhibiting nuclear loss of TDP-43 in LPS-treated hTDP-43A315T tg mice while arrows in third and fourth panel show neurons exhibiting nuclear loss of TDP-43 in vehicle-treated hTDP-43A315T tg mice. All representative sections are from different mice for each treatment group. DAPI was used to stain nuclei. Scale bar = 50μm. (B) Number of spinal neurons per section exhibiting nuclear loss of TDP-43 was higher in LPS-treated mice as compared to vehicle-treated mice (p = 0.043 by student’s t test, N = 4, 6 spinal cord sections from 4 different animals at 8 months were analyzed for each group).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Cited by

See all 131

Metadata

Authors
Correia, A. S., Patel, P., Dutta, K., & Julien, J.-P.
Affiliations
  • Centre hospitalier universitaire de Québec (CA)
  • Institut Universitaire en Santé Mentale de Québec (CA)
Corresponding author
Julien, Jean-Pierre
Venue
PLOS ONE
Published
2015-10-07
Volume
10
Issue
10
Pages
e0140248
ISSN
1932-6203 (ISSN-L)
OpenAlex
W1621668151
Cited by
114
References
39
Citations by year
2026: 5 · 2025: 14 · 2024: 14 · 2023: 9 · 2022: 12 · 2021: 17 · 2020: 10 · 2019: 11 · 2018: 9 · 2017: 6 · 2016: 6
FWCI
4.93
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Canadian Institutes of Health Research
Topics
  • Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
TDP-43, protein aggregation, mislocalization, neuroinflammation, lipopolysaccharide, microglia, astrocytes, TNF-α, amyotrophic lateral sclerosis, frontotemporal lobar degeneration, motor neurons, neurodegeneration
MeSH terms
Animals, Astrocytes, Cells, Cultured, DNA-Binding Proteins, Gene Expression Regulation, Humans, Inflammation, Lipopolysaccharides, Mice, Transgenic, RNA, Messenger, Point Mutation, Microglia, Mice, Protein Aggregates

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inflammation Induces TDP-43 Mislocalization and Aggregation. https://app.cochat.ai/papers/10.1371/journal.pone.0140248
The paper
Correia, A. S., Patel, P., Dutta, K., & Julien, J.-P. (2015). Inflammation Induces TDP-43 Mislocalization and Aggregation. PLOS ONE. https://doi.org/10.1371/journal.pone.0140248

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.